0001437749-24-000738.txt : 20240105 0001437749-24-000738.hdr.sgml : 20240105 20240105160535 ACCESSION NUMBER: 0001437749-24-000738 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20240105 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240105 DATE AS OF CHANGE: 20240105 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CervoMed Inc. CENTRAL INDEX KEY: 0001053691 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 300645032 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37942 FILM NUMBER: 24516239 BUSINESS ADDRESS: STREET 1: 20 PARK PLAZA STREET 2: SUITE 424 CITY: BOSTON STATE: MA ZIP: 02116 BUSINESS PHONE: (617) 744-4400 MAIL ADDRESS: STREET 1: 20 PARK PLAZA STREET 2: SUITE 424 CITY: BOSTON STATE: MA ZIP: 02116 FORMER COMPANY: FORMER CONFORMED NAME: Diffusion Pharmaceuticals Inc. DATE OF NAME CHANGE: 20160115 FORMER COMPANY: FORMER CONFORMED NAME: RestorGenex Corp DATE OF NAME CHANGE: 20140307 FORMER COMPANY: FORMER CONFORMED NAME: Stratus Media Group, Inc DATE OF NAME CHANGE: 20080722 8-K 1 crvo20240105_8k.htm FORM 8-K crvo20240105_8k.htm
false 0001053691 0001053691 2024-01-05 2024-01-05
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
___________________________
 
FORM 8-K
___________________________
 
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of The Securities Exchange Act of 1934
 
January 5, 2024
Date of Report (Date of earliest event reported)
___________________________
 
CervoMed Inc.
(Exact name of registrant as specified in its charter)
___________________________
 
Delaware
  
001-37942
  
30-0645032
(State or other jurisdiction
of incorporation)
  
(Commission
File Number)
  
(I.R.S. Employer
Identification No.)
   
20 Park Plaza, Suite 424
Boston, Massachusetts
  
02216
(Address of principal executive offices)
  
(Zip Code)
 
Registrant’s telephone number, including area code: (617) 744-4400
 
Not applicable
(Former name or former address, if changed since last report)
___________________________
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Title of each class
  
Trading
Symbol(s)
  
Name of each exchange
on which registered
Common Stock, $0.001 par value
  
CRVO
  
NASDAQ Capital Market
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
 
Emerging growth company ☐
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
 
 
 
 
 
Item 8.01         Other Events
 
On January 5, 2024, CervoMed Inc. (the “Company”) issued a press release announcing that members of the Company’s senior management team will present at the Emerging Growth Conference 66 on Thursday, January 11, 2024 at 11:25 a.m. ET. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
 
Item 9.01         Financial Statements and Exhibits
 
(d)         Exhibits
 
Exhibit No.
  
Description
     
99.1
  
104
  
Cover Page Interactive Data File (embedded within the Inline XBRL document).
 
 
 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
Date: January 5, 2024
CervoMed Inc.
 
By:         /s/ William Elder__________
Name:    William Elder
Title:       General Counsel
 
 
 
 EX-99.1 2 ex_612618.htm EXHIBIT 99.1 ex_612618.htm

Exhibit 99.1

 a01.jpg

 

CervoMed to Participate in the Emerging Growth Conference 66

 

Boston – January 5, 2024 – CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for degenerative diseases of the brain, today announced that Company’s Management will provide a corporate update at the Emerging Growth Conference 66, to be held virtually from January 10-11, 2024.

 

Presentation Details

Format: Corporate presentation

Date: Thursday, January 11, 2024

Time: 11:25 AM ET

Registration Link: click here

 

A live webcast of the presentation, along with accompanying slides, will be accessible here. A replay of the presentation will also be available through the conference portal and on the Emerging Growth YouTube Channel following the event.

 

About the Emerging Growth Conference

The Emerging Growth conference is an effective way for public companies to present and communicate their new products, services and other major announcements to the investment community from the convenience of their office, in a time efficient manner.

 

The Conference focus and coverage includes companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long term growth. Its audience includes potentially tens of thousands of Individual and Institutional investors, as well as Investment advisors and analysts.

 

All sessions will be conducted through video webcasts and will take place in the Eastern time zone.

 

About CervoMed

CervoMed Inc. is a clinical-stage biotechnology company focused on developing treatments for age-related neurologic disorders. The Company is currently developing neflamapimod, an investigational orally administered small molecule brain penetrant that inhibits p38MAP kinase alpha (p38a). Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that cause disease in dementia with Lewy bodies (DLB) and certain other major neurological disorders. Neflamapimod is currently being evaluated in a Phase 2b study in patients with DLB.

 

Investor Contact:

PJ Kelleher

LifeSci Advisors

Investors@cervomed.com

617-430-7579

 

 
 EX-101.SCH 3 crvo-20240105.xsd XBRL TAXONOMY EXTENSION SCHEMA 000 - Document - Document And Entity Information link:calculationLink link:definitionLink link:presentationLink EX-101.DEF 4 crvo-20240105_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 5 crvo-20240105_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity [Domain] Legal Entity [Axis] Document Information [Line Items] Document Information [Table] Document, Type Document, Period End Date Entity, Registrant Name Entity, Incorporation, State or Country Code Entity, File Number Entity, Tax Identification Number Entity, Address, Address Line One Entity, Address, City or Town Entity, Address, State or Province Entity, Address, Postal Zip Code City Area Code Local Phone Number Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security Trading Symbol Security Exchange Name Entity, Emerging Growth Company Amendment Flag Entity, Central Index Key EX-101.PRE 6 crvo-20240105_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 7 a01.jpg begin 644 a01.jpg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htm IDEA: XBRL DOCUMENT v3.23.4
Document And Entity Information
Jan. 05, 2024
Document Information [Line Items]  
Entity, Registrant Name CervoMed Inc.
Document, Type 8-K
Document, Period End Date Jan. 05, 2024
Entity, Incorporation, State or Country Code DE
Entity, File Number 001-37942
Entity, Tax Identification Number 30-0645032
Entity, Address, Address Line One 20 Park Plaza, Suite 424
Entity, Address, City or Town Boston
Entity, Address, State or Province MA
Entity, Address, Postal Zip Code 02216
City Area Code 617
Local Phone Number 744-4400
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock
Trading Symbol CRVO
Security Exchange Name NASDAQ
Entity, Emerging Growth Company false
Amendment Flag false
Entity, Central Index Key 0001053691
XML 9 crvo20240105_8k_htm.xml IDEA: XBRL DOCUMENT 0001053691 2024-01-05 2024-01-05 false 0001053691 8-K 2024-01-05 CervoMed Inc. DE 001-37942 30-0645032 20 Park Plaza, Suite 424 Boston MA 02216 617 744-4400 false false false false Common Stock CRVO NASDAQ false EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.4 html 1 22 1 false 0 0 false 0 false false R1.htm 000 - Document - Document And Entity Information Sheet http://www.crvo.com/20240105/role/statement-document-and-entity-information Document And Entity Information Cover 1 false false All Reports Book All Reports crvo-20240105.xsd crvo-20240105_def.xml crvo-20240105_lab.xml crvo-20240105_pre.xml crvo20240105_8k.htm http://xbrl.sec.gov/dei/2023 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "crvo20240105_8k.htm": { "nsprefix": "crvo", "nsuri": "http://www.crvo.com/20240105", "dts": { "schema": { "local": [ "crvo-20240105.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/currency/2023/currency-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/exch/2023/exch-2023.xsd", "https://xbrl.sec.gov/sic/2023/sic-2023.xsd", "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd" ] }, "definitionLink": { "local": [ "crvo-20240105_def.xml" ] }, "labelLink": { "local": [ "crvo-20240105_lab.xml" ] }, "presentationLink": { "local": [ "crvo-20240105_pre.xml" ] }, "inline": { "local": [ "crvo20240105_8k.htm" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 26, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 22 }, "report": { "R1": { "role": "http://www.crvo.com/20240105/role/statement-document-and-entity-information", "longName": "000 - Document - Document And Entity Information", "shortName": "Document And Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "d20248K", "name": "dei:EntityRegistrantName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "crvo20240105_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d20248K", "name": "dei:EntityRegistrantName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "crvo20240105_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.crvo.com/20240105/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.crvo.com/20240105/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.crvo.com/20240105/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.crvo.com/20240105/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document, Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.crvo.com/20240105/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.crvo.com/20240105/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.crvo.com/20240105/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.crvo.com/20240105/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.crvo.com/20240105/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.crvo.com/20240105/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_DocumentInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentInformationTable", "lang": { "en-us": { "role": { "label": "Document Information [Table]", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.crvo.com/20240105/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.crvo.com/20240105/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.crvo.com/20240105/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://www.crvo.com/20240105/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.crvo.com/20240105/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document, Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.crvo.com/20240105/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.crvo.com/20240105/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LegalEntityAxis", "presentation": [ "http://www.crvo.com/20240105/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.crvo.com/20240105/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.crvo.com/20240105/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityDomain", "presentation": [ "http://www.crvo.com/20240105/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity [Domain]", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://www.crvo.com/20240105/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentInformationLineItems", "presentation": [ "http://www.crvo.com/20240105/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.crvo.com/20240105/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.crvo.com/20240105/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 16 0001437749-24-000738-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001437749-24-000738-xbrl.zip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end